$CTSO
Cytosorbents Corp Stock $ctso

$ctso Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000114420419012774 Filed on March 07, 2019

Income Statement

Concept	2019 Q1	2018 Q4	2018 Q3
Revenue	$5.192M	$6.081M	$5.743M
YoY Change	5.42%	30.86%	50.17%
Cost Of Revenue	$1.739M	$2.080M	$2.053M
YoY Change	10.9%	63.78%	35.32%
Gross Profit	$3.453M	$3.998M	$3.690M
YoY Change	2.86%	18.21%	59.93%
Gross Profit Margin	66.51%	65.74%	64.26%
Selling, General & Admin	$4.758M	$7.160M	$4.041M
YoY Change	10.23%	50.1%	13.03%
% of Gross Profit	137.79%	179.11%	109.5%
Research & Development	$2.419M	$2.420M	$1.943M
YoY Change	40.19%	0.0%	202.15%
% of Gross Profit	70.04%	60.54%	52.66%
Depreciation & Amortization	$140.0K	$130.0K	$140.0K
YoY Change	133.33%	116.67%	133.33%
% of Gross Profit	4.05%	3.25%	3.79%
Operating Expenses	$7.738M	$9.590M	$6.401M
YoY Change	19.82%	33.57%	43.63%
Operating Profit	-$4.285M	-$5.585M	-$2.711M
YoY Change	38.18%	46.78%	26.13%
Interest Expense	-$205.2K	-$440.0K	-$185.2K
YoY Change	-14.19%	2100.0%	-27.01%
% of Operating Profit
Other Income/Expense, Net	-$598.6K		-$294.1K
YoY Change	-602.5%		-410.39%
Pretax Income	-$4.884M	-$6.020M	-$3.005M
YoY Change	63.77%	57.59%	46.27%
Income Tax	$0.00	-$620.0K	$0.00
% Of Pretax Income
Net Earnings	-$4.884M	-$5.400M	-$3.005M
YoY Change	63.77%	71.43%	46.27%
Net Earnings / Revenue	-94.07%	-88.8%	-52.32%
Basic Earnings Per Share	-$0.15
Diluted Earnings Per Share	-$0.15	-$170.4K	-$95.82K
COMMON SHARES
Basic Shares Outstanding	31.86M	31.65M shares	31.46M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q1	2018 Q4	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.60M	$22.40M	$24.90M
YoY Change	-7.11%	29.48%	61.69%
Cash & Equivalents	$19.65M	$22.37M	$24.91M
Short-Term Investments
Other Short-Term Assets	$700.0K	$1.100M	$600.0K
YoY Change	75.0%	175.0%	20.0%
Inventory	$1.214M	$833.1K	$779.4K
Prepaid Expenses
Receivables	$3.267M	$3.943M	$3.643M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$24.83M	$28.26M	$29.95M
YoY Change	1.28%	36.28%	54.38%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.897M	$1.730M	$1.677M
YoY Change	17.94%	23.32%	67.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.911M	$2.753M	$2.622M
YoY Change	33.54%	40.39%	45.67%
Total Long-Term Assets	$6.167M	$5.933M	$4.299M
YoY Change	62.79%	76.36%	51.79%
TOTAL ASSETS
Total Short-Term Assets	$24.83M	$28.26M	$29.95M
Total Long-Term Assets	$6.167M	$5.933M	$4.299M
Total Assets	$30.99M	$34.20M	$34.25M
YoY Change	9.51%	41.88%	54.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.841M	$1.486M	$1.859M
YoY Change	-13.97%	19.4%	43.03%
Accrued Expenses	$3.200M	$479.8K	$2.400M
YoY Change	77.78%	54.66%	60.0%
Deferred Revenue	$10.46K	$42.22K	$35.11K
YoY Change	-76.0%	38.97%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.667M	$666.7K	$0.00
YoY Change		-83.33%	-100.0%
Total Short-Term Liabilities	$6.711M	$6.917M	$4.261M
YoY Change	68.36%	-11.87%	-26.25%
LONG-TERM LIABILITIES
Long-Term Debt	$8.298M	$9.275M	$9.917M
YoY Change	-16.18%	54.78%	42.36%
Other Long-Term Liabilities	$1.000M	$1.100M
YoY Change
Total Long-Term Liabilities	$8.298M	$9.275M	$9.917M
YoY Change	-16.18%	54.78%	42.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.711M	$6.917M	$4.261M
Total Long-Term Liabilities	$8.298M	$9.275M	$9.917M
Total Liabilities	$15.98M	$17.26M	$14.18M
YoY Change	14.96%	24.72%	11.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$174.4M	-$169.5M	-$164.1M
YoY Change		11.3%	10.03%
Common Stock	$32.24K	$31.77K	$31.63K
YoY Change	7.57%	9.66%	11.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$15.01M	$16.93M	$20.07M
YoY Change
Total Liabilities & Shareholders Equity	$30.99M	$34.20M	$34.25M
YoY Change	9.52%	41.88%	54.15%

Cashflow Statement

Concept	2019 Q1	2018 Q4	2018 Q3
OPERATING ACTIVITIES
Net Income	-$4.884M	-$5.400M	-$3.005M
YoY Change	63.77%	71.43%	46.27%
Depreciation, Depletion And Amortization	$140.0K	$130.0K	$140.0K
YoY Change	133.33%	116.67%	133.33%
Cash From Operating Activities	-$4.238M	-$2.710M	-$2.630M
YoY Change	92.29%	560.98%	20.64%
INVESTING ACTIVITIES
Capital Expenditures	$292.5K	-$320.0K	-$280.0K
YoY Change	20.36%	-44.83%	-48.15%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change
Cash From Investing Activities	-$474.2K	-$320.0K	-$280.0K
YoY Change	0.41%	-44.83%	-48.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$0.00
YoY Change	-100.0%
Cash From Financing Activities	2.005M	480.0K	2.570M
YoY Change	-68.89%	-83.45%	52.07%
NET CHANGE
Cash From Operating Activities	-4.238M	-2.710M	-2.630M
Cash From Investing Activities	-474.2K	-320.0K	-280.0K
Cash From Financing Activities	2.005M	480.0K	2.570M
Net Change In Cash	-2.707M	-2.550M	-340.0K
YoY Change	-171.87%	-233.51%	-66.99%
FREE CASH FLOW
Cash From Operating Activities	-$4.238M	-$2.710M	-$2.630M
Capital Expenditures	$292.5K	-$320.0K	-$280.0K
Free Cash Flow	-$4.530M	-$2.390M	-$2.350M
YoY Change	85.14%	-1505.88%	43.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2018Q4	us-gaap	Liabilities Liabilities	15812726
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22368837
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17321862
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3943119
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2205859
CY2018Q4	us-gaap	Inventory Net InventoryNet	833133
CY2017Q4	us-gaap	Inventory Net InventoryNet	795657
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1118998
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	415962
CY2018Q4	us-gaap	Assets Current AssetsCurrent	28264087
CY2017Q4	us-gaap	Assets Current AssetsCurrent	20739340
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1729860
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1402782
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2753379
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1961185
CY2018Q4	us-gaap	Assets Assets	32747326
CY2017Q4	us-gaap	Assets Assets	24103307
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1485812
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1244411
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	666667
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4000000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6538199
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7848331
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9274527
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5992141
CY2017Q4	us-gaap	Liabilities Liabilities	13840472
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	31774
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	28974
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	186138466
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	162907482
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	288175
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-360985
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-169523815
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-152312636
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	16934600
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	10262835
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32747326
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24103307
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	83726
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	72697
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	990673
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	140724
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	848294
CY2017	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	687446
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31774139
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28973679
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31774139
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28973679
CY2018Q1	us-gaap	Revenues Revenues	4924651
CY2018Q2	us-gaap	Revenues Revenues	5755438
CY2018Q3	us-gaap	Revenues Revenues	5742975
CY2018Q4	us-gaap	Revenues Revenues	6080844
CY2018Q1	us-gaap	Gross Profit GrossProfit	3357006
CY2018Q2	us-gaap	Gross Profit GrossProfit	3969584
CY2018Q3	us-gaap	Gross Profit GrossProfit	3690278
CY2018Q4	us-gaap	Gross Profit GrossProfit	3997640
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3101167
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4187875
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2710620
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-5585266
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2982035
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5821202
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3004764
CY2018Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5403178
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2017Q1	us-gaap	Revenues Revenues	3113518
CY2017Q2	us-gaap	Revenues Revenues	3566226
CY2017Q3	us-gaap	Revenues Revenues	3824299
CY2017Q4	us-gaap	Revenues Revenues	4646711
CY2017Q1	us-gaap	Gross Profit GrossProfit	1859035
CY2017Q2	us-gaap	Gross Profit GrossProfit	2084216
CY2017Q3	us-gaap	Gross Profit GrossProfit	2307435
CY2017Q4	us-gaap	Gross Profit GrossProfit	3381708
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1557478
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2330908
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2149045
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-3805167
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1524873
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2070359
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2054279
CY2017Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3147019
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2016Q1	us-gaap	Revenues Revenues	1810182
CY2016Q2	us-gaap	Revenues Revenues	2222338
CY2016Q3	us-gaap	Revenues Revenues	2411708
CY2016Q4	us-gaap	Revenues Revenues	3083615
CY2016Q1	us-gaap	Gross Profit GrossProfit	990683
CY2016Q2	us-gaap	Gross Profit GrossProfit	1349072
CY2016Q3	us-gaap	Gross Profit GrossProfit	1447827
CY2016Q4	us-gaap	Gross Profit GrossProfit	1786536
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2090094
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2687371
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2144212
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-4570448
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1854596
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2814730
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2188119
CY2016Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4906011
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
CY2014Q2	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	43600
CY2017	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	41700
CY2016	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	35900
CY2018	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.2
CY2018	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05
CY2018	ctso	Cytosorb Sales Revenue CytosorbSalesRevenue	20143354
CY2017	ctso	Cytosorb Sales Revenue CytosorbSalesRevenue	13254953
CY2016	ctso	Cytosorb Sales Revenue CytosorbSalesRevenue	8206036
CY2018	ctso	Other Sales Revenue OtherSalesRevenue	109029
CY2017	ctso	Other Sales Revenue OtherSalesRevenue	126900
CY2016	ctso	Other Sales Revenue OtherSalesRevenue	0
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	20252383
CY2017	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	13381853
CY2016	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8206036
CY2018	ctso	Revenue From Grant RevenueFromGrant	2251525
CY2017	ctso	Revenue From Grant RevenueFromGrant	1768901
CY2016	ctso	Revenue From Grant RevenueFromGrant	1321807
CY2018	us-gaap	Revenues Revenues	22503908
CY2017	us-gaap	Revenues Revenues	15150754
CY2016	us-gaap	Revenues Revenues	9527843
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7489400
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5518360
CY2016	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3953725
CY2018	us-gaap	Gross Profit GrossProfit	15014508
CY2017	us-gaap	Gross Profit GrossProfit	9632394
CY2016	us-gaap	Gross Profit GrossProfit	5574118
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7723028
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17211179
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8796530
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11763456
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3221233
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4073093
CY2018	us-gaap	Professional Fees ProfessionalFees	2002032
CY2017	us-gaap	Professional Fees ProfessionalFees	1339493
CY2016	us-gaap	Professional Fees ProfessionalFees	1184788
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20874376
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14914266
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11808362
CY2018	us-gaap	Operating Expenses OperatingExpenses	30599436
CY2017	us-gaap	Operating Expenses OperatingExpenses	19474992
CY2016	us-gaap	Operating Expenses OperatingExpenses	17066243
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-15584928
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-9842598
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-11492125
CY2018	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1461045
CY2017	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-749076
CY2016	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-231804
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-784752
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1454136
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-358077
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2245797
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	705060
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-589881
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-17211179
CY2018	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0
CY2017	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	335731
CY2016	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.46
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30719176
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27613911
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25433719
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-8460799
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-11763456
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	649160
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1259669
CY2016	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	314367
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16562019
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9720468
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11449089
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	9846715
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2631734
CY2016	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	125059
CY2016	ctso	Stock Issued During Period Value Stock Cash Warrants Exercised StockIssuedDuringPeriodValueStockCashWarrantsExercised	65000
CY2016	ctso	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	0
CY2016	ctso	Stock Issued During Period Value Stock Cash Options Exercised StockIssuedDuringPeriodValueStockCashOptionsExercised	118040
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	1337459
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3313603
CY2017	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	207608
CY2017	ctso	Stock Issued During Period Value Stock Cash Warrants Exercised StockIssuedDuringPeriodValueStockCashWarrantsExercised	853004
CY2017	ctso	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	0
CY2017	ctso	Stock Issued During Period Value Stock Cash Options Exercised StockIssuedDuringPeriodValueStockCashOptionsExercised	591899
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0
CY2017	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	0
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4437250
CY2018	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	545693
CY2018	ctso	Stock Issued During Period Value Stock Cash Warrants Exercised StockIssuedDuringPeriodValueStockCashWarrantsExercised	1280456
CY2018	ctso	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	0
CY2018	ctso	Stock Issued During Period Value Stock Cash Options Exercised StockIssuedDuringPeriodValueStockCashOptionsExercised	2206860
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0
CY2018	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	637000
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2477279
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.56
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M12D
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1044219
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.68
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	695770
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.12
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	27351
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	114.33
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	36200
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.26
CY2016	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm	P2Y6M
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2762177
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.69
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1204950
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.46
CY2017	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm	P9Y2M12D
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	165720
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.50
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	34020
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	34.61
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	188849
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.40
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3578538
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.64
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M18D
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1481675
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.01
CY2018	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm	P9Y2M12D
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	544671
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.49
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	800
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	2.88
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	856280
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.65
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3658462
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.82
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2016	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2016	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2016	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2017	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2017	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2016	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	454807
CY2016	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	2192000
CY2017	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	691480
CY2016	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	431352
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	390551
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	218271
CY2017	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2018	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2018	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2018	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2018Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	2406845
CY2018Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	4.96
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	7517438
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1070959
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	3.31
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.88
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	524674
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	4.53
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	776343
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.62
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1251617
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	4.56
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	430358
CY2018	us-gaap	Other Noncash Expense OtherNoncashExpense	637000
CY2018	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	947910
CY2016	us-gaap	Depreciation And Amortization DepreciationAndAmortization	161613
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	14762
CY2017	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	904
CY2016	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	65378
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-784752
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1454136
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-358077
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	4437250
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	3313603
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	2756793
CY2018	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts	97041
CY2017	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts	82054
CY2016	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts	30480
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1847848
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	649318
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	889715
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	56751
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-57320
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-340392
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	731672
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	76981
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-187099
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	6345
CY2017	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	15000
CY2016	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	41112
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1704845
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-168103
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1632132
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10839684
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6460705
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6730967
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	671970
CY2017	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1560
CY2016	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5000000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1596469
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	666667
CY2017	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5000000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1520264
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1678119
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	666667
CY2018	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	147988
CY2016	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	118833
CY2018	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	14126525
CY2017	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	13679730
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2206860
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	591899
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	118040
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1280456
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	853004
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	65000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17465853
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20123073
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5064207
CY2018	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-58930
CY2017	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	92435
CY2016	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-1382
CY2018	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5046975
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	12076684
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-71673
CY2018	us-gaap	Interest Paid Net InterestPaidNet	891386
CY2017	us-gaap	Interest Paid Net InterestPaidNet	634608
CY2016	us-gaap	Interest Paid Net InterestPaidNet	175897
CY2018	us-gaap	Stock Issued1 StockIssued1	545693
CY2017	us-gaap	Stock Issued1 StockIssued1	207608
CY2017	ctso	Dividend Warrant Exercise Price Adjustment DividendWarrantExercisePriceAdjustment	335731
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5245178
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5316851
CY2018	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1. BASIS OF PRESENTATION</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements include the results of CytoSorbents Corporation (the “Parent”), CytoSorbents Medical Inc., its wholly-owned operating subsidiary (the “Subsidiary”), and CytoSorbents Europe GmbH, its wholly-owned European subsidiary (the “European Subsidiary”). In addition, the financial statements include CytoSorbents Switzerland GmbH and CytoSorbents Poland Sp. z.o.o., wholly-owned subsidiaries of CytoSorbents Europe GmbH. These entities are collectively referred to as “the Company”.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Based on its projections, the Company believes it will have to raise additional capital to fund its planned operations over the next twelve-month period.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2018, the Company had an accumulated deficit of $169,523,815, which included net losses of $17,211,179 for the year ended December 31, 2018, $8,460,799 for the year ended December 31, 2017 and $11,763,456 for the year ended December 31, 2016. The Company’s losses have resulted principally from costs incurred in the research and development of the Company’s polymer technology and selling, general and administrative expenses. The Company intends to continue to conduct significant additional research, development, and clinical study activities which, together with expenses incurred for the establishment of manufacturing arrangements and a marketing and distribution presence and other selling, general and administrative expenses, are expected to result in continuing operating losses for the foreseeable future. The amount of future losses and when, if ever, the Company will achieve profitability are uncertain. The Company’s ability to achieve profitability will depend, among other things, on successfully completing the development of its technology and commercial products, obtaining additional requisite regulatory approvals in markets not covered by the CE mark previously received for the Company’s CytoSorb product and for potential label extensions of the Company’s current CE mark, establishing manufacturing and sales and marketing arrangements with third parties, and raising sufficient funds to finance the Company’s activities. No assurance can be given that the Company’s product development efforts will be successful, that the Company’s current CE mark will enable it to achieve profitability, that additional regulatory approvals in other countries will be obtained, that any of the Company’s products will be manufactured at a competitive cost and will be of acceptable quality, or that the Company will be able to achieve profitability or that profitability, if achieved, can be sustained. These matters raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments related to the outcome of this uncertainty.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities. Actual results could differ from these estimates. Significant estimates in these financials are the valuation of options granted and valuation methods used to determine the change in fair value of the down round feature related to certain of the Company’s outstanding warrants.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Concentration of Credit Risk</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">A significant portion of our revenues are from product sales in Germany. Substantially all of our grant and other income are from grant agencies in the United States. (See Note 3 for further information relating to the Company’s revenue.)</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2018, two distributors/strategic partners accounted for <div style="letter-spacing: 0px; top: 0px;;display:inline;">29</div> percent of the outstanding grants and accounts receivables. As of December 31, 2017, two distributors/strategic partners accounted for <div style="letter-spacing: 0px; top: 0px;;display:inline;">28</div> percent of outstanding grants and accounts receivables. As of December 31, 2016, one distributor/strategic partners and one government agency accounted for approximately <div style="letter-spacing: 0px; top: 0px;;display:inline;">22</div> percent of grants and accounts receivable. For the years ended December 31, 2018 and 2017, no agency, distributor/strategic partners or direct customer represented more than <div style="letter-spacing: 0px; top: 0px;;display:inline;">10</div>% of the Company’s total revenue. For the year ended December 31, 2016, one direct customer accounted for approximately <div style="letter-spacing: 0px; top: 0px;;display:inline;">11</div> percent of total revenue.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018	us-gaap	Reclassifications Reclassifications	<div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reclassifications</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Certain reclassifications have been made to the December 31, 2018, 2017 and 2016 financial statements in order to conform to the 2018 financial statement presentation. There was no change in the reported amount of the accumulated deficit as a result of these reclassifications.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	213839
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	151872
CY2018Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	415265
CY2017Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	528039
CY2018Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	204029
CY2017Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	115746
CY2018	us-gaap	Advertising Expense AdvertisingExpense	212000
CY2017	us-gaap	Advertising Expense AdvertisingExpense	162000
CY2016	us-gaap	Advertising Expense AdvertisingExpense	173000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	495870
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	270249
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	72022
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	838141
CY2018	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	805000
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	676000
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	473000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3725061
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-14105664
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-6071009
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-9300042
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3066529
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2781964
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-17830725
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-9137538
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-12082006
CY2018	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-619546
CY2017	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-676739
CY2016	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-318550
CY2018	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	0
CY2017	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	0
CY2016	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	0
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-619546
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-676739
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-318550
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16722801
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12517356
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15227562
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1210153
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1096308
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1121722
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	-27098
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	74477
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	213791
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18255666
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14167174
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17169956
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18233810
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14147354
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17152066
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	21856
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	19820
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	17890
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	21856
CY2017Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	19820
CY2016Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	17890
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0
CY2017Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0
CY2016Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.022
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.026
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.041
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.019
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.014
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.010
CY2018	ctso	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Percent EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent	-0.029
CY2017	ctso	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Percent EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent	-0.051
CY2016	ctso	Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Percent EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent	-0.084
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.076
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.627
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.060
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.229
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.443
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.137
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.007
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.008
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.018
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.032
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.073
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.026
CY2019Q1	ctso	Proceeds From Sale Of Net Operating Loss Carryforwards ProceedsFromSaleOfNetOperatingLossCarryforwards	619546
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3904803
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-3004712
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2405975
CY2017Q4	ctso	Clinical Study Costs Payable Current ClinicalStudyCostsPayableCurrent	111394
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	479783
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	310227
CY2018Q4	ctso	Accrued Salaries And Commissions Current AccruedSalariesAndCommissionsCurrent	1840457
CY2017Q4	ctso	Accrued Salaries And Commissions Current AccruedSalariesAndCommissionsCurrent	1009913
CY2018Q4	ctso	Clinical Study Costs Payable Current ClinicalStudyCostsPayableCurrent	822085
CY2018Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	433589
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	334335
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	280381
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	300351
CY2018Q4	ctso	Accrued Travel And Entertainment Expence Current AccruedTravelAndEntertainmentExpenceCurrent	187047
CY2017Q4	ctso	Accrued Travel And Entertainment Expence Current AccruedTravelAndEntertainmentExpenceCurrent	164985
CY2018Q4	ctso	Sales Payroll And Income Taxes Payable Current SalesPayrollAndIncomeTaxesPayableCurrent	182753
CY2017Q4	ctso	Sales Payroll And Income Taxes Payable Current SalesPayrollAndIncomeTaxesPayableCurrent	178592
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent	76726
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	78585
CY2018Q4	ctso	Congresses Payable Current CongressesPayableCurrent	51549
CY2017Q4	ctso	Congresses Payable Current CongressesPayableCurrent	72291
CY2018Q4	ctso	Accrued Director Fees Current AccruedDirectorFeesCurrent	31350
CY2017Q4	ctso	Accrued Director Fees Current AccruedDirectorFeesCurrent	28500
CY2018Q4	ctso	Customer Deposit Current CustomerDepositCurrent	0
CY2017Q4	ctso	Customer Deposit Current CustomerDepositCurrent	14747
CY2018Q4	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	4385720
CY2017Q4	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	2603920
CY2018Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000
CY2017Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000
CY2018Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	105681
CY2017Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	75567
CY2018Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	46875
CY2017Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	67708
CY2018Q4	us-gaap	Long Term Debt LongTermDebt	9941194
CY2017Q4	us-gaap	Long Term Debt LongTermDebt	9992141
CY2018Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	2399662
CY2017Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1267459
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	42219
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	30380
CY2018Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	666667
CY2018Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	4000000
CY2018Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	1333333
CY2018Q4	ctso	Long Term Debt And Final Fee LongTermDebtAndFinalFee	10000000
CY2018	us-gaap	Depreciation Depreciation	329469
CY2017	us-gaap	Depreciation Depreciation	177776
CY2016	us-gaap	Depreciation Depreciation	126112
CY2018Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	4000000
CY2018	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2094140
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4904212
CY2018	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	17718000
CY2016	us-gaap	Adjustment For Amortization AdjustmentForAmortization	35501
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	78900
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	78000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	76400
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	73100
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4258210
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1838052
CY2018Q4	us-gaap	Security Deposit SecurityDeposit	128114
CY2017Q4	us-gaap	Security Deposit SecurityDeposit	123133
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	69800
CY2018Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	68791
CY2018Q2	us-gaap	Other Noncash Expense OtherNoncashExpense	637000
CY2015Q3	ctso	Aggregate Registered Amount For Offerings AggregateRegisteredAmountForOfferings	150000000
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10300000
CY2014Q1	us-gaap	Share Price SharePrice	4.50
CY2015Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	28880
CY2017	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	550000
CY2018	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1515260
CY2018Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2929517
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2081222
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	304252
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	243170
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2625265
CY2018	us-gaap	Adjustment For Amortization AdjustmentForAmortization	61082
CY2017	us-gaap	Adjustment For Amortization AdjustmentForAmortization	40495
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4437000
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3314000
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2757000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q4	us-gaap	Share Price SharePrice	8.08
CY2018Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	943000
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	531900
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	668550
CY2018Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1200450
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested	5636000
CY2018	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	3381000
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	953200
CY2017Q1	ctso	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedInPeriodFairValue	3284000
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	810220
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	900100
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3174352
CY2016Q2	ctso	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedInPeriodFairValue	2437000
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	716480
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2855428
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0209
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0311
CY2018	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	0
CY2017	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	0
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13679730
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14126525
CY2018	ctso	License Period LicensePeriod	P18Y
CY2018Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	9.61
CY2018	ctso	Share Based Compensation Option Milestones Met By The Company Percentage ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage	0.6
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2018	dei	Document Type DocumentType	10-K
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Entity Registrant Name EntityRegistrantName	Cytosorbents Corp
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0001175151
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2018Q2	dei	Entity Public Float EntityPublicFloat	320079293
CY2018	dei	Trading Symbol TradingSymbol	CTSO
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	31855099
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2018	dei	Entity Small Business EntitySmallBusiness	true
CY2017	us-gaap	Other Noncash Expense OtherNoncashExpense	0
CY2016	us-gaap	Other Noncash Expense OtherNoncashExpense	0
CY2018	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0
CY2017	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0
CY2017	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0
CY2016	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0
CY2016	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	0
CY2016	us-gaap	Stock Issued1 StockIssued1	0
CY2018	ctso	Dividend Warrant Exercise Price Adjustment DividendWarrantExercisePriceAdjustment	0
CY2016	ctso	Dividend Warrant Exercise Price Adjustment DividendWarrantExercisePriceAdjustment	0
CY2018Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	41400000

Files In Submission

Name	View Source	Status
0001144204-19-012774-index-headers.html	Edgar Link	pending
0001144204-19-012774-index.html	Edgar Link	pending
0001144204-19-012774.txt	Edgar Link	pending
0001144204-19-012774-xbrl.zip	Edgar Link	pending
ctso-20181231.xml	Edgar Link	completed
ctso-20181231.xsd	Edgar Link	pending
ctso-20181231_cal.xml	Edgar Link	unprocessable
ctso-20181231_def.xml	Edgar Link	unprocessable
ctso-20181231_lab.xml	Edgar Link	unprocessable
ctso-20181231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_001.gif	Edgar Link	pending
image_003.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv514648_10k.htm	Edgar Link	pending
tv514648_ex10-23.htm	Edgar Link	pending
tv514648_ex10-24.htm	Edgar Link	pending
tv514648_ex21-1.htm	Edgar Link	pending
tv514648_ex23-1.htm	Edgar Link	pending
tv514648_ex31-1.htm	Edgar Link	pending
tv514648_ex31-2.htm	Edgar Link	pending
tv514648_ex32-1.htm	Edgar Link	pending
tv514648_ex32-2.htm	Edgar Link	pending
tv514648_img-1.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTSO
Cytosorbents Corp Stock $ctso

2019 Q1 Form 10-K Financial Statement

#000114420419012774 Filed on March 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSO Cytosorbents Corp Stock $ctso

2019 Q1 Form 10-K Financial Statement

#000114420419012774 Filed on March 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSO
Cytosorbents Corp Stock $ctso